Sugi Predict

Sugi Predict / Compounds / SCHEMBL610128

SCHEMBL610128

SCHEMBL610128

CC(C)(C)OC(=O)N1CC=CC[C@H]1C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 1/20 0.42
▸ PREP P48147 1/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ LMNA P02545 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ CYP1A2 P05177 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ CHRM2 P08172 1/20 0.35
▸ CHRM1 P11229 1/20 0.35
▸ CHRM3 P20309 1/20 0.35
▸ NPC1 O15118 1/20 0.34
▸ GPR119 Q8TDV5 1/20 0.34
▸ CTSK P43235 1/20 0.33
▸ USP2 O75604 1/20 0.33
▸ ATM Q13315 1/20 0.33
▸ NR1H2 P55055 1/20 0.33
▸ NR1H3 Q13133 1/20 0.33
▸ MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16824590 1.00 HSD17B10 (0.42) HSD17B10PREPSMN1; SMN2LMNANPSR1
SCHEMBL16824591 1.00 HSD17B10 (0.42) HSD17B10PREPSMN1; SMN2LMNANPSR1
SCHEMBL4864324 0.84 HSD17B10 (0.46) HSD17B10SMN1; SMN2LMNANPSR1NPC1
SCHEMBL7870376 0.84 NR1H2 (0.43) HSD17B10PREPSMN1; SMN2LMNANPSR1
SCHEMBL30477339 0.80 PREP (0.41) HSD17B10PREPSMN1; SMN2LMNANPSR1
SCHEMBL26765821 0.80 PREP (0.41) HSD17B10PREPSMN1; SMN2LMNANPSR1
SCHEMBL31399260 0.80 SMN1; SMN2 (0.40) PREPSMN1; SMN2LMNANPSR1CYP1A2
SCHEMBL28202604 0.79 CHRM2 (0.42) HSD17B10PREPSMN1; SMN2LMNANPSR1
SCHEMBL5649423 0.77 PREP (0.37) HSD17B10PREPSMN1; SMN2CHRM2CHRM1
SCHEMBL24155186 0.77 FKBP1A (0.47) MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208992-A1 MACROCYCLES AS CFTR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2024-06-27 — — US disclosed
EP-4308575-A1 MACROCYCLES AS CFTR MODULATORS Idorsia Pharmaceuticals Ltd (CH) 2024-01-24 — — EP disclosed
EP-3533797-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2023-12-20 — — EP disclosed
CN-116981672-A Macrocyclic compounds as CFTR modulators 爱杜西亚药品有限公司 2023-10-31 — — CN disclosed
US-20230225323-A1 COMPOSITIONS AND METHODS FOR PARASITE CONTROL PHILIP MORRIS PRODUCTS S.A. (CH) 2023-07-20 — — US disclosed
US-11649229-B2 Amide compounds for treatment of immune and inflammatory disorders ACHILLION PHARMACEUTICALS, INC. (US) 2023-05-16 — — US disclosed
CN-115698002-A Compositions and methods for parasite control 菲利普莫里斯生产公司 2023-02-03 — — CN disclosed
WO-2022194399-A1 MACROCYCLES AS CFTR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2022-09-22 — — WO disclosed
WO-2021260029-A1 COMPOSITIONS AND METHODS FOR PARASITE CONTROL PHILIP MORRIS PRODUCTS S.A. (CH) 2021-12-30 — — WO disclosed
CN-106928127-B Substituted piperidine amide derivative, preparation method and pharmaceutical application thereof 四川海思科制药有限公司 2021-07-16 — — CN disclosed
EP-2421850-A1 3 -AZABICYCLO [4.1.0]HEPTANES USED AS OREXIN ANTAGONISTS Glaxo Group Limited (GB) 2012-02-29 — — EP disclosed
US-20120040991-A1 3-AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS GLAXO GROUP LIMITED (GB) 2012-02-16 — — US disclosed
US-20120040991-A1 3-AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS GLAXO GROUP LIMITED (GB) 2012-02-16 — — US disclosed
US-20120040991-A1 3-AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS GLAXO GROUP LIMITED (GB) 2012-02-16 — — US disclosed
EP-2370426-A1 N-{[(IR,4S,6R-3-(2-PYRIDINYLCARBONYL)-3-AZABICYCLO [4.1.0]HEPT-4-YL]METHYL}-2-HETEROARYLAMINE DERIVATIVES AND USES THEREOF Glaxo Group Limited (GB) 2011-10-05 — — EP disclosed
WO-2010122151-A1 3 -AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS GLAXO GROUP LIMITED (GB) 2010-10-28 — — WO disclosed
US-20100144760-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2010-06-10 — — US disclosed
US-20100144760-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2010-06-10 — — US disclosed
US-20100144760-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2010-06-10 — — US disclosed
WO-2010063663-A1 N-{[(IR,4S,6R-3-(2-PYRIDINYLCARBONYL)-3-AZABICYCLO [4.1.0]HEPT-4-YL] METHYL}-2-HETEROARYLAMINE DERIVATIVES AND USES THEREOF GLAXO GROUP LIMITED (GB) 2010-06-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230225323-A1 COMPOSITIONS AND METHODS FOR PARASITE CONTROL TRHDE, CUTA, PIGS HSD17B10 4388/4885PREP 2318/4885SMN1; SMN2 1876/4885
US-11649229-B2 Amide compounds for treatment of immune and inflammatory disorders CFD, TFPI, CFH HSD17B10 2518/4885PREP 356/4885SMN1; SMN2 4650/4885
US-20240208992-A1 MACROCYCLES AS CFTR MODULATORS CFTR, PKD1, ARRB1 HSD17B10 2713/4885PREP 4336/4885SMN1; SMN2 3983/4885
US-20100144760-A1 NOVEL COMPOUNDS HTR3B, HTR1B, HTR2B HSD17B10 2206/4885PREP 4524/4885SMN1; SMN2 1195/4885
US-20120040991-A1 3-AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS HCRTR2, HCRTR1, NPY2R HSD17B10 577/4885PREP 2178/4885SMN1; SMN2 2847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.